Showing 1-10 of 12 results for "".
Unlocking the Latest in Toxins: A Discussion of Market Trends and FDA Breakthroughs With Dr. Joely Kaufman
https://modernaesthetics.com/topics/injectables/unlocking-the-latest-in-toxins-a-discussion-of-market-trends-and-fda-breakthroughs-with-dr-joely-kaufman/35409/Do You Need to Provide a Good Faith Estimate for a Botox Treatment?
https://modernaesthetics.com/topics/injectables/do-you-need-to-provide-a-good-faith-estimate-for-a-botox-treatment/35210/Recent updates from CMS still don’t mention aesthetics specifically, but there are indications that some aesthetic and dermatology services require a GFE.Does the No Surprises Act Apply to Aesthetic Services?
https://modernaesthetics.com/topics/practice-development/does-the-no-surprises-act-apply-to-aesthetic-services-1/35152/What do you need to disclose before a procedure?Expanding the Role for Topical Carboxytherapy: An Advisory Board Discussion
https://modernaesthetics.com/ma-issues-index/2024-mar-apr/expanding-the-role-for-topical-carboxytherapy-an-advisory-board-discussion/35355/Aesthetics and Wellness
https://modernaesthetics.com/topics/skincare/aesthetics-and-wellness/36076/Exploring two increasingly intertwined pursuitsWhere Are We in 2023? A Q&A on Botulinum Toxins
https://modernaesthetics.com/ma-issues-index/2023-nov-dec/where-are-we-in-2023-a-qa-on-botulinum-toxins/35332/Sue Ellen Cox, MD, describes what she is seeing in the evolving neuromodulators landscapeInteroperability Update
https://modernaesthetics.com/ma-issues-index/2017-may-june/interoperability-update/34272/Are PHRs the key to interoperability?Update on the Neurotoxin Pipeline
https://modernaesthetics.com/topics/injectables/update-on-the-neurotoxin-pipeline/35246/A look at the current landscape and the near horizon.- Mark Kaufmann, MDhttps://modernaesthetics.com/profiles/mark-kaufmann-md/Lx6qnj/
- Sandra Kaufmann, MDhttps://modernaesthetics.com/profiles/sandra-kaufmann-md/LgywDV/
- Prev
- Next